Ahmet Tezel Adds to LivaNova PLC Holdings

Ahmet Tezel, the Chief Innovation Officer at LivaNova PLC, recently purchased 2,965 shares of the company. The transaction took place on June 15, 2026, with shares trading at $79.48 on the NasdaqGS under the ticker LIVN.

Insider Buying and Selling at LivaNova PLC

On June 15, 2026, several insiders at LivaNova PLC made notable stock transactions. Ahmet Tezel, the Chief Innovation Officer, acquired 2,965 shares. Alongside him, Francesco Bianchi and Stacy Enxing Seng each purchased 2,383 shares. Meanwhile, Donald Zurbay sold 308 shares at an average price of $79.70, and Francesco Bianchi also sold 4,042 shares. Todd Schermerhorn bought 4,042 shares on the same day.

Other Institutional Activity in LivaNova

In recent institutional activity, BlackRock, Inc. reduced its holdings by 184,614 shares, ending with 7,138,908 shares valued at approximately $453.75 million. Primecap Management Co/CA/ also trimmed its position by 17,800 shares, bringing its total to 4,207,052 shares worth about $267.40 million. On the other hand, FMR LLC significantly increased its stake, adding 2,620,791 shares to hold a total of 2,666,674 shares valued at $169.49 million. AQR Capital Management LLC boosted its position by 339,230 shares, ending with 2,494,372 shares worth $154.38 million. Conversely, Millennium Management LLC cut its stake by 1,045,411 shares, holding 2,438,671 shares valued at $155.00 million.

LivaNova PLC Stock Snapshot

Shares of LivaNova PLC, trading under the ticker LIVN on NasdaqGS, are priced at $79.48. The company boasts a market cap of $4.31 billion and a P/E ratio of 40.05, with a forward P/E of 16.95. Its beta stands at 0.884. The stock's 52-week range is between $41.02 and $80.96, with a 50-day moving average of $69.67 and a 200-day moving average of $62.48. LivaNova maintains a current ratio of 1.33 and a quick ratio of 1.009, with a debt-to-equity ratio of 28.35.

Recent Earnings

LivaNova PLC reported revenue of $1.43 billion, experiencing a growth rate of 14.3%. The company achieved a net margin of 7.48% and a return on equity of 9.54%. Earnings per share stood at $1.96. The next earnings report is expected on August 5, 2026.

Analysts Set New Price Targets

On May 7, 2026, Barclays maintained its 'hold' rating on LivaNova with a price target of $76. Mizuho also maintained a 'buy' rating, setting a target price of $90. Baird continued to recommend a 'buy' with a $76 target. Overall, the consensus among analysts is a 'buy' rating, with a mean target price of $80.60 based on 10 analyst opinions.

About LivaNova PLC

LivaNova PLC is a medical technology company based in London, United Kingdom. It designs and sells medical devices and therapies across the globe, focusing on two main areas: Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment offers products like heart-lung machines and oxygenators, while the Neuromodulation segment includes devices for treating epilepsy and depression. Led by CEO Mr. Vladimir A. Makatsaria, LivaNova employs approximately 3,300 people worldwide.

Bottom Line

Ahmet Tezel's recent purchase of LivaNova shares highlights insider confidence in the company's prospects. LivaNova continues to be a key player in the medical devices sector, with a strong market presence and a diverse product portfolio. Investors often track insider transactions like these as potential indicators of a company's future performance. However, it's important to remember that insider trades are just one of many factors to consider when evaluating a stock.